Difference between revisions of "Breast cancer, PIK3CA-mutated"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Solid tumors" to "Category:Malignant solid neoplasm") |
|||
| Line 49: | Line 49: | ||
[[Category:Breast cancer regimens]] | [[Category:Breast cancer regimens]] | ||
[[Category:Biomarker-specific pages]] | [[Category:Biomarker-specific pages]] | ||
| − | [[Category: | + | [[Category:Malignant solid neoplasm]] |
Revision as of 23:52, 11 January 2020
3 regimens on this page
3 variants on this page
|
Note: this page has regimens which are specific to breast cancer that is PIK3CA-mutated. Please see the main breast cancer page for other chemotherapy regimens.
Advanced or metastatic disease, all lines of therapy
Alpelisib & Fulvestrant
| back to top |
Regimen
| FDA-recommended dose |
| Study | Evidence | Comparator | Comparative Efficacy | Years of study |
|---|---|---|---|---|
| André et al. 2019 (SOLAR-1) | Phase III (E-RT-esc) | Fulvestrant | Superior PFS | 2015-2017 |
Note: patients enrolled in this trial had HR-positive breast cancer.
Chemotherapy
- Alpelisib (Piqray) 300 mg PO once per day
Hormonotherapy
- Fulvestrant (Faslodex) as follows:
- Cycle 1: 500 mg IM once per day on days 1 & 15
- Cycle 2 onwards: 500 mg IM once on day 1
28-day cycles
References
- SOLAR-1: André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, Iwata H, Conte P, Mayer IA, Kaufman B, Yamashita T, Lu YS, Inoue K, Takahashi M, Pápai Z, Longin AS, Mills D, Wilke C, Hirawat S, Juric D; SOLAR-1 Study Group. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med. 2019 May 16;380(20):1929-1940. link to original article contains verified protocol PubMed